168 related articles for article (PubMed ID: 31945665)
1. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
Zhou L; Chen W; Cao C; Shi Y; Ye W; Hu J; Wang L; Zhou W
Eur J Med Chem; 2020 Mar; 189():112028. PubMed ID: 31945665
[TBL] [Abstract][Full Text] [Related]
2. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W
Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
[TBL] [Abstract][Full Text] [Related]
4. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors.
Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J
Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors.
Dong J; Wang Z; Cui J; Meng Q; Li S
Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators.
Chen D; Fan Q; Xu T; Dong J; Cui J; Wang Z; Wang J; Meng Q; Li S
Anticancer Agents Med Chem; 2022; 22(2):261-269. PubMed ID: 33820523
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme.
Sharma R; Gatchie L; Williams IS; Jain SK; Vishwakarma RA; Chaudhuri B; Bharate SB
Bioorg Med Chem Lett; 2017 Dec; 27(24):5400-5403. PubMed ID: 29150398
[TBL] [Abstract][Full Text] [Related]
8. Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance.
Yao X; Mao J; Zhang H; Xiao Y; Wang Y; Liu H
Eur J Med Chem; 2024 Jun; 272():116488. PubMed ID: 38733885
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Cytochrome P450 1B1 Targeted Molecular Imaging Probes for Colorectal Tumor Detection.
Meng Q; Wang Z; Cui J; Cui Q; Dong J; Zhang Q; Li S
J Med Chem; 2018 Dec; 61(23):10901-10909. PubMed ID: 30422652
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of selective CYP1B1 inhibitor via dearomatization of α-naphthoflavone.
Kubo M; Yamamoto K; Itoh T
Bioorg Med Chem; 2019 Jan; 27(2):285-304. PubMed ID: 30553624
[TBL] [Abstract][Full Text] [Related]
11. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity.
Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D
J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063
[TBL] [Abstract][Full Text] [Related]
12. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs.
Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F
Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468
[TBL] [Abstract][Full Text] [Related]
13. Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.
Poirier D; Roy J; Cortés-Benítez F; Dutour R
Bioorg Med Chem Lett; 2016 Nov; 26(21):5272-5276. PubMed ID: 27687674
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme.
Bournique B; Lemarié A
Drug Metab Dispos; 2002 Nov; 30(11):1149-52. PubMed ID: 12386117
[TBL] [Abstract][Full Text] [Related]
15. Biphenyl urea derivatives as selective CYP1B1 inhibitors.
Mohd Siddique MU; McCann GJ; Sonawane V; Horley N; Williams IS; Joshi P; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
Org Biomol Chem; 2016 Sep; 14(38):8931-8936. PubMed ID: 27714268
[TBL] [Abstract][Full Text] [Related]
16. A new class of CYP1B1 inhibitors derived from bentranil.
Yi L; Huang X; Yang M; Cai J; Jia J; Peng Z; Zhao Z; Yang F; Qiu D
Bioorg Med Chem Lett; 2023 Jan; 80():129112. PubMed ID: 36565966
[TBL] [Abstract][Full Text] [Related]
17. Scaffold hopping for designing of potent and selective CYP1B1 inhibitors to overcome docetaxel resistance: synthesis and evaluation.
Raju B; Narendra G; Verma H; Kumar M; Sapra B; Kaur G; Jain SK; Sandeep Chary P; Mehra NK; Silakari O
J Biomol Struct Dyn; 2024 Feb; ():1-19. PubMed ID: 38356135
[TBL] [Abstract][Full Text] [Related]
18. Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.
Chang I; Mitsui Y; Fukuhara S; Gill A; Wong DK; Yamamura S; Shahryari V; Tabatabai ZL; Dahiya R; Shin DM; Tanaka Y
Oncotarget; 2015 Apr; 6(10):7774-87. PubMed ID: 25860934
[TBL] [Abstract][Full Text] [Related]
19. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance.
McFadyen MC; McLeod HL; Jackson FC; Melvin WT; Doehmer J; Murray GI
Biochem Pharmacol; 2001 Jul; 62(2):207-12. PubMed ID: 11389879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
